Incorporation of NKT Cell-Activating Glycolipids Enhances Immunogenicity and Vaccine Efficacy of Mycobacterium bovis
Bacillus Calmette-Guérin M ycobacterium tuberculosis remains one of the major causes of global morbidity and mortality from infectious disease. Currently, it is estimated that one-third of the people on the planet are infected with this organism, with the majority of these representing latent infections with the potential for reactivation leading to active disease and transmission (1) . Approximately 2 million people die from tuberculosis (TB) 3 every year, making it the second highest cause of death from an infectious disease worldwide after HIV/AIDS (2, 3) . The only currently available vaccine for prevention of TB, the M. bovis strain bacillus Calmette-Guérin (BCG), has had little impact on halting the progression of the global TB epidemic (3) . A wide range of epidemiologic studies demonstrate that vaccination with BCG provides partial protection against TB in newborns, but has minimal or no efficacy in preventing latent TB or reactivation of pulmonary disease in adults (4) . In addition, the growing prevalence of TB and the emergence of extensively drug-resistant strains of M. tuberculosis, has stimulated substantial efforts to develop better vaccines for TB by either improving or replacing BCG (5-7). These efforts have focused largely on enhancing the priming and maintenance of T cell responses against mycobacterial Ags, which are believed to be central to protective immunity against M. tuberculosis. Studies in animal models and observations in human subjects demonstrate the importance of Ag-specific T cell responses in controlling infections with M. tuberculosis (8) . Experiments in mice with specific gene deletions support a major role for MHC class II-restricted CD4 ϩ T cells in the control of experimental TB (9) . CD4 ϩ T cells may exert their protective function in TB largely through the secretion of T H 1 type cytokines including IFN-␥ and other factors that stimulate the bactericidal activities of M. tuberculosis-infected macrophages and dendritic cells (DCs). In addition, recent data indicate a potential role for CD4 ϩ IL-17-producing (T H 17) T cells in vaccine-induced immunity to M. tuberculosis (10) . MHC class I-restricted CD8 ϩ T cells also contribute to protective immunity in TB, although most studies have indicated that they play a less prominent role than CD4 ϩ T cells in acute and chronic M. tuberculosis infection (8, 11) . Recent work indicates that M. tuberculosis possesses multiple mechanisms to delay or prevent the priming of both MHC class I-and class II-restricted T cell responses (5, 12, 13) . Similar immune evasion properties are also likely to be operational in BCG, providing an explanation for the failure of this attenuated mycobacterium to provide strong protective immunity against M. tuberculosis. The development of methods to overcome the immune evasion properties inherent in live attenuated vaccines such as BCG is thus of central relevance to the creation of more effective vaccines for prevention of TB.
NKT cells are an unconventional T cell subset that has the potential when activated to augment many types of immune responses and may thus offer a potential strategy for augmenting the immunogenicity of vaccines such as BCG. Among the defined subsets of NKT cells, the most abundant and well-studied are those with an invariant TCR␣ chain and are known as type 1 or invariant NKT (iNKT) cells. These T cells recognize glycolipid Ags presented by the nonpolymorphic MHC class I-like CD1d molecule and display a wide variety of regulatory and effector activities upon activation (14, 15) . A few natural lipid and glycolipid Ags recognized by iNKT cells have been described, but much more extensive studies have been conducted using synthetic glycolipid ligands that mimic natural CD1d-presented Ags. The prototype and most widely analyzed iNKT cell agonist is a synthetic form of ␣-galactosylceramide with a saturated 26-carbon acyl chain and a C18 phytosphingosine base (referred to here as ␣GalCer; Fig. 1A ) (16) . A single injection of ␣GalCer into mice activates the entire population of iNKT cells, directly stimulating the rapid release of multiple cytokines and also secondary activation of NK cells, DCs, B cells, and conventional T cells (17) (18) (19) . Activation of iNKT cells in vivo by injections of ␣GalCer has beneficial effects in a wide variety of mouse infection and tumor models, including chronic infections with M. tuberculosis and other highly persistent pathogens (20, 21) .
Among the many chemically modified forms of ␣GalCer, a synthetic analog containing a C-glycoside in place of the usual Oglycosidic bond (␣-C-GalCer; Fig. 1A ) has been shown to have superior activity compared with ␣GalCer for enhancing T H 1-type immunity. In direct comparisons with ␣GalCer, injection of mice with the ␣-C-GalCer analog has been shown to produce better immune responses against tumors and improved resolution of infections with malaria parasites (22) . Like ␣GalCer and to an even greater extent, the ␣-C-GalCer analog induces markedly increased and sustained levels of IFN-␥ and IL-12p70 in mice, which are two of the cytokines that are well established to be essential for control of TB in mice and humans (23) . Based on these observations, we hypothesized that iNKT cell activation with these glycolipids, in conjunction with priming of T cells against mycobacterial vaccine Ags, could lead to improved adaptive responses against virulent mycobacteria. 14 C]␣GalCer indicated on the x-axis was added to glass vials in chloroform:methanol 2:1 and the solvent completely evaporated. The y-axis indicates cpm recovered with each solvent when used to redissolve the glycolipid as determined by beta scintillation counting of an aliquot of the resulting solutions. C, Growth rate of BCG cultures (monitored by OD at 600 nm (OD 600 )) in protein-free Middlebrook 7H9 medium with 0.05% tyloxapol. D, To determine the optimal concentration of ␣GalCer for incorporation into live BCG, the bacteria were grown in Middlebrook 7H9 medium with 0.05% tyloxapol containing a range of concentrations of [ 14 C]␣GalCer. After growth for 6 days to an OD 600 of ϳ0.8, cultures were harvested and ␣GalCer incorporation was determined by beta scintillation counting of extensively washed bacteria (percent incorporated indicates cpm in the washed bacterial pellet divided by total cpm of [ 14 C]␣GalCer added to the culture initially ϫ 100). E, ␣GalCer remained intact following incorporation into live BCG. Autoradiograph of a TLC plate is shown.
14 C-containing lipids extracted from BCG grown for 8 days (OD 600 ϭ 0.7) with 16 g/ml [
14 C]␣GalCer in Middlebrook 7H9 medium with 0.05% tyloxapol (lane 2) had identical mobility as the [ 14 C]␣GalCer reference standard (lane 1). Quantitation of the autoradiographic signals from the TLC plate confirmed that ϳ25% of the radiolabeled glycolipid added to the original culture was stably incorporated into the bacteria as intact ␣GalCer.
In this study, we have developed an approach for stably incorporating ␣GalCer and its analog ␣-C-GalCer into live BCG organisms and have evaluated the impact of this on the stimulation of T cell responses and protective immunity. We found that live BCG containing relatively small amounts of incorporated ␣GalCer retained the ability to robustly activate iNKT cells. Compared with immunization with unmodified BCG, the glycolipid-modified BCG stimulated increased maturation of DCs and markedly augmented the priming of Ag-specific CD8 ϩ T cells responses. A single intradermal immunization of mice with the glycolipid-modified BCG also provided a significantly higher level of protective immunity than standard BCG vaccination against an aerosol challenge with M. tuberculosis strain H37Rv. These results provide the basis for a simple modification of BCG that could overcome the CD8 ϩ T cell priming defect inherent in this vaccine and potentially lead to a more effective vaccine for prevention and control of M. tuberculosis infections.
Materials and Methods

Mice
Six-to 8-wk-old female wild-type C57BL/6 and BALB/c mice and B6.PL (Thy1.1 ϩ ) mice were obtained from The Jackson Laboratory.
CD1D
Ϫ/Ϫ mice (C57BL/6 background) were provided by M. Exley and S. Balk (Harvard Medical School, Boston, MA) (24) . J␣18 Ϫ/Ϫ mice (C57BL/6 background) were a gift from M. Taniguchi and T. Nakayama (Chiba University, Chiba, Japan) (25) . C57BL/6 Rag-1
OT-I TCR-transgenic mice were obtained from the National Institute of Allergy and Infectious Diseases Exchange Program at Taconic Farms. C57BL/6 background p25TCR-Tg/Rag-1 Ϫ/Ϫ mice were described previously (26) and were bred in our facility from founders provided by Dr. J. Ernst (New York University School of Medicine, New York, NY). All mice were maintained in specific pathogen-free conditions and were transferred to biosafety level 3 conditions following infection with M. tuberculosis. All procedures involving the use of animals were in compliance with protocols approved by the Einstein Institutional Animal Use and Biosafety Committees.
Glycolipids
␣GalCer was synthesized as previously described (27) . The 14 C-labeled ␣-GalCer was synthesized using the same method except that [1- 14 C] arachidonic acid (Sigma-Aldrich) was used in place of the C26:0 fatty acid to provide ␣GalCer- [1- 14 C]C20:4 as an intermediate, which was then hydrogenated to yield ␣GalCer- [1- 14 C]C20:0 (sp. act., 183 Ci/mg). The use of 14 C-␣GalCer-C20:0 for these studies, although not optimal, was necessary because of technical limitations that have so far precluded synthesis of a radiolabeled form with longer N-acyl chains (e.g., C26:0) that are present in the most immunologically active forms of ␣GalCer. The ␣-C-GalCer was obtained from the National Institutes of Health Tetramer Core Facility (http://www.niaid.nih.gov/reposit/tetramer/overview.html). Both glycolipids were stored as solvent-free aliquots in glass vials at Ϫ20°C and were reconstituted either in 100% DMSO at 100 M for in vitro studies or in aqueous vehicle consisting of PBS with 0.05% Tween 20 and 0.1% DMSO at 500 M for in vivo studies.
Bacterial strains
M. bovis BCG (Danish strain) was obtained from Statens Serum Institute (Copenhagen, Denmark) and the recombinant BCG-OVA strain (derived from BCG-Pasteur transformed with plasmid pMO230 encoding codons 230 -359 of chicken OVA fused to the Ag 85B signal sequence) was a gift from Dr. S. Sad (National Research Council-Institute for Biological Sciences, Ottawa, Ontario, Canada). These strains were grown in protein-free Middlebrook 7H9 medium (M7H9; Difco Laboratories) with 0.05% tyloxapol (Sigma-Aldrich). Virulent M. tuberculosis strain H37Rv (obtained from the Trudeau Institute) was grown in M7H9 supplemented with the oleic acid-albumin-dextrose complex (Difco Laboratories). Bacterial CFU titers were determined by plating tissue homogenates or aliquots of bacterial suspension on Middlebrook 7H11 agar plates containing oleic acid-albumin-dextrose complex and 2 g/ml thiophene-2-carboxylic acid hydrazide (Sigma-Aldrich) to inhibit growth of residual BCG from immunized mice.
Incorporation of glycolipids into live BCG
Unlabeled ␣GalCer or ␣-C-GalCer or 14 C-labeled ␣GalCer were solubilized at 200 g/ml in glass vials with protein-free M7H9 medium containing 0.5% tyloxapol by sonicating for 5 min, heating at 80°C for 2 min, and vortexing for 1 min. The solubilized glycolipid was immediately diluted in protein-free M7H9 to give the required concentration of glycolipid and a final concentration of 0.05% tyloxapol. M. bovis BCG (mid-log phase culture, OD 600 0.5-0.8) was inoculated (200 l into 10 ml of M7H9 with 0.05% tyloxapol plus glycolipid) and grown to mid-log phase (OD 600 0.5-1.0), which generally required 7-10 days. The bacteria were harvested by centrifugation, washed thoroughly with PBS plus 0.05% tyloxapol, and resuspended in PBS plus 0.05% tyloxapol for injection or use in cell culture experiments. In the case of cultures grown with 14 C-labeled ␣GalCer, bacteria were washed thoroughly with PBS plus 0.05% tyloxapol, dried, and lipid incorporation was assessed by beta scintillation counting.
Thin-layer chromatography
For analysis of extractable cell wall lipids, M. bovis BCG was grown with 14 C-labeled ␣GalCer to an OD 600 of 0.5. The cell pellet was washed and incubated overnight in a mixture of chloroform:methanol (2:1), after which the solvent was collected and dried under a stream of nitrogen. The extracted lipids were resuspended in chloroform and spotted onto silica TLC plates (Alltech Associates) for separation using a solvent mixture composed of chloroform, methanol, and water (60:16:2). After running solvent front to within ϳ1 cm of the top, the plates were dried and analyzed by autoradiography using a 24-h exposure to x-ray film.
Primary cell suspensions and cell lines
Bone marrow-derived DC (BMDC) from C57BL/6 and BALB/c mice were prepared based on a published protocol (28) . The V␣14i NKT hybridoma DN3A4-1.2 was provided by M. Kronenberg (La Jolla Institute for Allergy and Immunology, La Jolla, CA). Spleen cell suspensions were prepared by gently forcing spleen tissue through a 70-m cell strainer. Liver mononuclear cells were isolated by treating the liver tissue with Liberase Blendzyme 2 (Roche Applied Science) and using a density gradient of 45 and 67.5% Percoll. Human monocyte-derived DCs were prepared by treatment of normal random donor blood monocytes with GM-CSF and IL-4 as previously described (29) . Human CD4 Ϫ CD8 Ϫ iNKT cell clone HDE3 was established from normal donor blood and cultivated using previously described methods (30) .
In vitro assays of iNKT cell activation
For the mouse iNKT hybridoma assay, BMDC were infected with BCG, ␣GalCer/BCG, or ␣-C-GalCer/BCG at a multiplicity of infection (MOI) of 10:1 for 2 h at 37°C, followed by washing to remove extracellular bacteria, and cultured at numbers indicated with mouse iNKT hybridoma DN3A4-1.2 (5 ϫ 10 4 cells) for 16 h. Supernatants were assayed for IL-2 by ELISA. For splenocyte or hepatic mononuclear cell stimulations, splenocytes were plated at 5 ϫ 10 5 cells/well or liver mononuclear cells were plated at 4 ϫ 10 5 cells/well with the indicated numbers of C57BL/6 BMDCs infected at a MOI of 10:1 with BCG, ␣GalCer/BCG, or ␣-C-GalCer/BCG. After 48 h, supernatant levels of IL-4 and IFN-␥ were measured by ELISA using capture and biotinylated detection Ab pairs (BD Biosciences). For human iNKT cell clone activation, human monocyte-derived DCs were infected with live BCG with or without glycolipid incorporation at an MOI of 5:1 and incubated at various numbers with human CD4
Ϫ CD8 Ϫ iNKT cell clone HDE3 (5 ϫ 10 4 cells/well). Supernatant samples were harvested after 24 h and assayed by capture ELISA using Ab pairs for IFN-␥, TNF-␣ (both from Pierce/ThermoScientific) and IL-13 (BD Biosciences).
In vivo assay of iNKT cell activation
Mice were given i.p. injections of inert vehicle (PBS plus 0.01% Tween 20 plus 0.1% DMSO or PBS plus 0.05% tyloxapol), free glycolipids (␣GalCer or ␣-C-GalCer, 4 g in 0.2 ml vehicle), or BCG suspensions (unmodified or glycolipid-modified BCG at 5 ϫ 10 6 CFU/mouse in 0.2 ml of PBS plus 0.05% tyloxapol). Sera were assayed at the indicated times for IL-4, IL12p70, and IFN-␥ by capture ELISA as previously described (27) .
Multiparameter FACS analyses
All experiments requiring analysis of more than four fluorescence parameters were performed using an LSR II flow cytometer (BD Biosciences). Aggregates were excluded by gating on cells with equivalent forward scatter height/forward scatter area profiles, and dead cells were excluded by gating on Blue Live/Dead viability dye (BluVID; Molecular Probes)-negative cells. Data analysis was performed using FlowJo software (Tree Star).
For analysis of in vivo DC maturation, wild-type C57BL/6 or CD1d Ϫ/Ϫ mice were injected i.p. with unmodified or glycolipid-modified BCG (5 ϫ 10 6 CFU/mouse in 0.2 ml of PBS plus 0.05% tyloxapol). Splenocytes and hepatic mononuclear cells were harvested 40 h later and stained with Blu-VID. The cells were then blocked with rat anti-mouse Fc␥II/III clone 2.4G2 in PBS plus 2% FCS and labeled with mAbs against CD11c and CD45R/B220 (PE-Cy7 and allophycocyanin-Cy7 conjugates; BD Biosciences). Biotin-labeled mAbs against one of the following were also added to replicate samples: CD80, CD86, MHC class II, and CD70 (eBioscience). After incubation with streptavidin-Alexa Fluor 405 (Invitrogen), cells were fixed with 0.5% paraformaldehyde and analyzed. DCs were identified by gating on CD11c high B220 neg cells. For analysis of multifunctional CD4 ϩ T cells, splenocytes and lung mononuclear cells were prepared from animals vaccinated intradermally 2 mo previously and restimulated with 20 g/ml total sonicate of M. tuberculosis H37Rv or 5 g/ml Ag85B peptide p25 plus 1 g/ml soluble anti-CD28 mAb (eBioscience). After incubation (37°C, 5% CO 2 ) for 2 h, 10 g/ml brefeldin A (Sigma-Aldrich) was added for an additional 4 h. Cells were labeled with BluVID, blocked with mAb 2.4G2, and stained with anti-CD3e-FITC, anti-CD4-allophycocyanin-Cy7, and anti-CD8␣-Pacific Blue (BD Biosciences). Cells were fixed with 2% paraformaldehyde, washed with permeabilization buffer (PBS with 1 mM Ca 2ϩ , 1 mM Mg 2ϩ , 1 mM HEPES, 2% FCS, and 0.1% saponin), and then blocked in permeabilization buffer plus 10% normal mouse serum (Jackson ImmunoResearch Laboratories). The following mAbs were then added: anti-IL-2-allophycocyanin, anti-IFN-␥-Alexa Fluor 700, and anti-TNF-␣-PE-Cy7 (BD Biosciences).
For analysis of CD4 ϩ regulatory T cells (Treg), single-cell suspensions were stained with BluVID, followed by blocking with 2.4G2 and surface staining with anti-CD3-FITC, anti-CD4-allophycocyanin-Cy7, and anti-CD25-PE (BD Biosciences). Cells were then prepared for intracellular staining using a FoxP3 staining kit (eBioscience) according to the manufacturer's instructions and stained with anti-FoxP3-Alexa Fluor 647 (eBioscience).
IFN-␥ ELISPOT assay
Splenic T cells were purified using the Dynal Mouse T Cell Negative Isolation Kit (Invitrogen). The separated T cells were cultured in ELISPOT plates (Millipore) coated with IFN-␥ capture Ab (clone R4.6A2; BD Biosciences). Purified T cells (1 ϫ 10 5 /well) were added to the plate in complete medium (0.1 ml/well) with splenocytes from a naive mouse (9 ϫ 10 5 /well) and the antigenic peptides (5 g/ml) for 24 h at 37°C. After removal of cells, plates were washed with PBS followed by PBS with 0.05% Tween 20 (PBST). Biotinylated anti-IFN-␥ detection Ab (clone 4S.B3; BD Biosciences) was added for 2 h at 37°C, followed by washing with PBST. Streptavidin-alkaline phosphatase (Sigma-Aldrich) was added to the plates for 1 h (37°C), followed by washing and addition of 5-bromo-4-chloro-3-indolyl phosphate/NBT substrate (Sigma-Aldrich). The reaction was stopped by washing the wells with water, and spots were counted using an ELISPOT reader (Autoimmun Diagnostika).
Assessment of in vivo T cell proliferation by CFSE dilution
Donor splenocytes were isolated from p25TCR-Tg/Rag-1
ϩ T cell analysis) and labeled with 10 M CFSE. Recipient B6.PL (Thy1.1 ϩ ) mice received 5 ϫ 10 6 labeled cells via the lateral tail vein and were then vaccinated s.c. with 5 ϫ 10 6 CFU of glycolipid-modified or unmodified BCG or BCG-OVA as indicated or PBS plus 0.05% tyloxapol as negative control. Splenocytes were harvested 5-7 days later, stained with anti-Thy1.2-allophycocyanin, anti-B220-PerCP, and either anti-CD8-PE or anti-CD4-PE Abs (BD Biosciences), and analyzed using a FACSCalibur flow cytometer (BD Biosciences). CFSE fluorescence of the transferred population was determined by gating on the B220 neg CD8 ϩ or CD4 ϩ lymphocytes expressing Thy1.2.
Vaccination and challenge studies
Wild-type C57BL/6 mice or iNKT cell-deficient CD1d Ϫ/Ϫ or J␣18
Ϫ/Ϫ mice were vaccinated intradermally with either unmodified or glycolipidmodified BCG (5 ϫ 10 6 CFU/mouse in 0.2 ml of PBS plus 0.05% tyloxapol). Aerogenic challenge was done 2 mo later using a whole-body exposure aerosol chamber (Mechanical Engineering Workshop) custom fitted to a class III biosafety cabinet (Baker) to deliver 50 -100 CFU per animal of virulent M. tuberculosis (strain H37Rv). Mice were sacrificed at 3 and 6 wk after challenge. Lungs and spleens of individual mice were aseptically removed, homogenized using a Seward Stomacher 80 blender (Tekmar), and plated on Middlebrook 7H11 agar. Lung tissues were processed for histopathology using standard paraffin fixation, sectioning, and H&E staining.
Statistical analyses
GraphPad Prism 5.0 software was used for statistical analyses. One-way ANOVA and unpaired Student's t test were used to compare the experimental groups. The Bonferroni multiple comparison test (for six or fewer groups) or the Tukey multiple comparison test (for more than six groups) were used to generate p values for selected pairwise comparisons, and p Ͻ 0.05 were considered significant.
Results
Stable incorporation of ␣GalCer into live BCG
Previous studies on the use of ␣GalCer as an adjuvant for enhancing T cell responses to protein Ags have shown the importance of administering the glycolipid at the same site as the Ag (31). This is likely to reflect the need to activate iNKT cells at the surface of the same APCs that are actively engaged in the processing and presentation of the Ag to achieve a strong adjuvant effect. To optimize the delivery of ␣GalCer to the same APCs that become infected by BCG during vaccination, we developed an approach that enabled the glycolipid to be physically incorporated into the cell wall or membranes of the bacterium. Mycobacteria such as BCG are surrounded by an outer membrane-like structure composed of mycolic acids and other extremely hydrophobic lipid molecules, and studies have demonstrated that exogenous lipids can be incorporated into this structure without affecting viability of the bacteria (32) . Although such lipid transfer in mycobacteria has generally been done using the organic solvent petroleum ether, we found that the limited solubility of ␣GalCer in this solvent prevented the use of that method (Fig. 1B) . We therefore examined the solubility of ␣GalCer in aqueous solutions of the detergents Tween 80 and tyloxapol, which are routinely used in mycobacterial culture medium and are known to be compatible with the growth of BCG.
Using a 14 C-labeled preparation of a biologically active C20 N-acyl form of ␣GalCer ( 14 C-␣GalCer-C20:0), we observed excellent solubilization of the glycolipid in PBS containing 0.05% tyloxapol, which was comparable to solubility in a 2:1 choroform: methanol mixture and clearly superior to PBS containing 0.05% Tween 80 (Fig. 1B) . The growth of BCG in liquid medium containing 0.05% tyloxapol was unaffected by the addition of ␣GalCer or ␣-C-GalCer, indicating that these glycolipids did not have toxic effects on the bacteria (Fig. 1C) . The colony counts obtained by plating BCG on standard growth medium were also unaffected by their growth in medium containing ␣GalCer (data not shown). Growth of BCG in protein-free medium with 0.05% tyloxapol and various concentrations of 14 C-labeled ␣GalCer demonstrated that greater than 20% of the added radiolabel became stably incorporated into the bacteria (i.e., not removed by repeated washing of bacterial pellet with PBS plus 0.05% tyloxapol) when the glycolipid was initially added at a concentration of 16 g/ml or greater (peak incorporation of 28% at 32 g/ml; Fig. 1D ). Lipids were re-extracted from BCG grown in medium containing 16 g/ml 14 C-labeled ␣GalCer and analyzed by TLC, which revealed that the majority of the incorporated glycolipid migrated identically to the standard preparation of ␣GalCer and was therefore chemically intact (Fig. 1E) .
Biologic activity of glycolipids incorporated into live BCG
For the initial assessment of the biological activity of iNKT cellactivating glycolipids incorporated into live BCG, we used a standard iNKT cell hybridoma stimulation assay (27) . BCG grown in medium containing 20 g/ml ␣GalCer (␣GalCer/BCG) or its related ␣-C-GalCer (␣-C-GalCer/BCG) were prepared, and the extensively washed bacteria were used to infect cultures of mouse BMDCs. The DCs infected with glycolipid-modified BCG preparations strongly stimulated IL-2 production by iNKT cell hybridoma cells in comparison to DCs infected with unmodified BCG, indicating that the incorporated glycolipids could be released during intracellular growth or processing of the bacteria and presented by CD1d molecules (Fig. 2A) . We observed similar activity when iNKT cell hybridoma cells were activated by holding the number of infected BMDCs constant but varying the MOI of BCG or glycolipid-modified BCG (supplemental Fig. 1  4 ) . Strong cytokine responses were also observed when BMDCs infected with ␣GalCer/ BCG were cocultured with mouse splenocytes, with significant levels of IFN-␥ and IL-4 accumulating in the culture supernatant after 48 h as is typical for primary iNKT cell responses (Fig. 2B) . Interestingly, with splenocytes as the source of the responding iNKT cells, we did not observe any cytokine production using ␣-C-GalCer/BCG. However, with liver mononuclear cells which are highly enriched in iNKT cells, we were able to observe a significant IFN-␥ response to ␣-C-GalCer-modified BCG without detectable IL-4 (Fig. 2C) . These findings were consistent with the limited activity of ␣-C-GalCer that has been generally observed in cell culture assays (M. M. Venkataswamy and S. A. Porcelli, unpublished data), which contrasts strongly with the marked in vivo activity of this glycolipid in mice. In addition, the absence of detectable IL-4 in the in vitro response of hepatic mononuclear cells to ␣-C-GalCer/BCG suggested a strongly T H 1-biased iNKT cell response, which is consistent with in vivo studies using this analog in mice (22) .
We also tested the activity of ␣GalCer/BCG or ␣-C-GalCer/ BCG for stimulation of a human iNKT cell clone in cultures with infected monocyte-derived human DCs. This demonstrated that ␣GalCer/BCG was strongly stimulatory toward human iNKT cells and activated their secretion of IFN-␥, TNF-␣, and IL-13 at relative levels comparable to those obtained with addition of free ␣GalCer (Fig. 2D and additional data not shown) . These results were consistent with the known conservation of many of the features of iNKT cell responses between humans and mice (33) . Similar to the mouse splenocyte cultures, no activity for ␣-C-GalCer/ BCG was observed in this in vitro human iNKT cell culture 4 The online version of this article contains supplemental material. system. Although the question of whether or how strongly human iNKT cells can respond to ␣-C-GalCer has not been clearly resolved, one previous study has reported that cultured human iNKT cells can be activated by this glycolipid (34) . By analogy with the observations in the mouse system, it is very possible that ␣-CGalCer could be a strongly activating ligand for human iNKT cells in vivo, but for reasons that remain unclear this activity is difficult to reveal using available in vitro assays.
Injection of ␣GalCer into mice by i.v. or i.p. routes is known to induce a robust systemic response that is manifested by easily detectable levels of serum cytokines (27) . To determine the in vivo activity of the glycolipids incorporated stably into live BCG, we measured serum cytokine levels at various time points after i.p. injection of ␣GalCer/BCG into C57BL/6 mice. ␣GalCer/BCG was clearly active in vivo and induced low but detectable serum levels of IFN-␥, IL-12, and IL-4 within 6 -12 h (Fig. 2E) . Intraperitoneal injection of unmodified BCG induced low levels of serum IL12p70 and no detectable IFN-␥ or IL-4 over a 48-h period, whereas a single injection of free ␣GalCer rapidly induced all three cytokines as previously described (35) . Serum cytokines were not detected in similar experiments conducted using CD1d Ϫ/Ϫ or J␣18 Ϫ/Ϫ knockout mice, which are both completely deficient in iNKT cells (data not shown). Interestingly, although injection of free ␣-C-GalCer gave strong and sustained serum IFN-␥ levels with no detectable IL-4 as previously reported (22), we detected only minimal augmentation of serum IFN-␥ at 24 h with i.p. injection of BCG modified by incorporation of ␣-C-GalCer (data not shown).
Since ␣GalCer and ␣-C-GalCer have been reported to induce differentiation and maturation of DCs, we also assessed expression of MHC class II and costimulatory molecules on the CD11c ϩ cells in the spleens and livers of C57BL/6 mice that were injected i.p with ␣GalCer/BCG or ␣-C-GalCer/BCG. In the spleen (Fig. 3A) , neither unmodified nor glycolipid-modified BCG had a significant effect on the surface levels of MHC class II molecules. However, the costimulatory molecules CD80, CD86, and CD70, while only slightly increased on CD11c ϩ cells by unmodified BCG, showed pronounced induction with ␣GalCer/BCG and also to a lesser extent with ␣-C-GalCer/BCG. In the liver mononuclear cell fraction (Fig. 3B) , marked increases of MHC class II were observed with both ␣GalCer/BCG and ␣-C-GalCer/BCG, as well as increases in CD80, CD86, and CD70. In all cases, these effects were greater than those observed with unmodified BCG. We also verified that these effects depended on iNKT cell activation, since they did not occur in parallel experiments conducted in CD1D Ϫ/Ϫ knockout mice which lack iNKT cells (data not shown). These results strongly suggested that the enhancement of DC maturation was an important consequence resulting from incorporation of iNKT cell agonist glycolipids into BCG.
Influence of glycolipid incorporation on Ag-specific T cell priming
Given the known effects of free ␣GalCer on the priming of Agspecific T cells and the effects observed on DC maturation with glycolipid-modified BCG, we assessed the impact of incorporating iNKT cell agonist glycolipids into BCG on the priming of both CD4 ϩ and CD8 ϩ T cells. Surprisingly, using a variety of different methods to assess CD4 ϩ T cell responses against an immunodominant secreted mycobacterial Ag (peptide 25 of Ag 85B, or p25), we were unable to detect any change in CD4 ϩ responses with incorporation of either ␣GalCer or ␣-C-GalCer into BCG (Fig. 4) . This included the initial priming of naive T cells specific for the p25 epitope as assessed by the cell division of adoptively transferred p25-specific TCR-transgenic T cells during the first week of immunization (Fig. 4A) . Analysis of this response using lower doses of BCG (10 4 CFU) also failed to reveal any augmentation of the response with glycolipid incorporation (supplemental Fig. 2A) . Similarly, analysis by the IFN-␥ ELISPOT assay of responses against p25 at 3 or 8 wk (Fig. 4B) after immunization revealed uniformly strong responses in animals that received unmodified or glycolipid-modified BCG. Multiparameter FACS analyses revealed no differences in the percentages of CD4 ϩ T cells that simultaneously produced IFN-␥, IL-2, and TNF-␣ (multifunctional or polyfunctional T cells (36) ), or in the levels of FoxP3 ϩ and CD25 ϩ Treg (37)) in the spleen ( Fig. 4C and supplemental Fig.  2B ) or lungs (data not shown) of animals immunized with the various BCG preparations, indicating that CD4 ϩ T cell differentiation proceeded similarly in mice immunized with unmodified and glycolipid-modified BCG.
In marked contrast to our findings on CD4 ϩ T cell responses, evaluation of Ag-specific CD8 ϩ T cell priming and recall responses revealed a dramatic effect of the glycolipid incorporation. To facilitate analysis of this component of the T cell response, we took advantage of a recombinant BCG expressing a fragment of OVA containing the immunodominant H-2K b -presented OVA 257-264 epitope (SIINFEKL) (38) . To directly observe the priming of MHC class I-restricted CD8 ϩ T cells in the context of vaccination, we used adoptive transfer of CFSE-labeled naive T cells from SIINFEKL/H-2K b -reactive TCR-transgenic OT-I mice (5). Thy1.1 ϩ B6.PL mice were injected with CFSE-labeled Thy1.2 ϩ splenocytes from OT-I mice, followed by vaccination either with BCG-OVA, ␣GalCer/BCG-OVA, or ␣-CGalCer/BCG-OVA. CD8 ϩ T cell activation and proliferation were assessed by dilution of CFSE in the transferred population at 5-7 days after infection (Fig. 5A) . Only minimal activation and proliferation of transferred OT-I T cells was observed in mice infected with BCG-OVA, as ϳ80% of the remaining Thy1.2 ϩ cells had CFSE levels that indicated a failure to undergo division. In contrast, ␣GalCer/BCG-OVA or ␣-C-GalCer/BCG-OVA infection induced a massive increase in proliferation of transferred T cells. Nearly all detectable Thy1.2 ϩ T cells had diluted their CFSE staining to backgrounds levels and the size of the Thy1.2 ϩ population had increased substantially, indicating survival and accumulation of the proliferating CD8 ϩ T cells. Similar results were observed for cells from the spleen (Fig. 5A) and from the draining lymph nodes (supplemental Fig. 3) .
To analyze recall responses of endogenous CD8 ϩ T cells, C57BL/6 mice were vaccinated with unmodified or glycolipidmodified BCG-OVA and analyzed after 3 or 8 wk for SIINFEKLresponsive CD8
ϩ T cells in the spleen by IFN-␥ ELISPOT (Fig.  5B) . This revealed significantly enhanced responses to the Responses to this peptide were also significantly enhanced in BALB/c mice vaccinated 2 wk previously with ␣GalCer/BCG compared with unmodified BCG (Fig. 5C ). Taken together, these results provided strong evidence that mycobacterial Ag-specific CD8 ϩ T cell responses were significantly accelerated and enhanced by incorporation of ␣GalCer or ␣-C-GalCer into live BCG.
Experiments were also conducted to address the question of whether the effect of ␣GalCer or ␣-C-GalCer on enhancing CD8 ϩ T cell responses required the physical association of the glycolipids with the immunizing bacteria. The effects on CD8 ϩ T cell priming of free glycolipids injected at a separate site from unmodified BCG, or of injection of the two components at the same site by mixing the free glycolipid with the bacteria immediately before injection, were compared with administration of the glycolipidmodified BCG (Fig. 5D ). This revealed that only direct physical incorporation of the glycolipids into live BCG organisms was able to induce significantly improved CD8 ϩ T cell priming against an H-2K b presented TB10.3/10.4 epitope (QIMYNPAM) (39) . Comparable findings were also obtained using BCG-OVA with analysis of the H-2K b -presented SIINFEKL epitope in C57BL/6 mice (data not shown). The difference between directly incorporated vs free ␣GalCer or ␣-C-GalCer was apparent with a dose of 0.1 g of glycolipid (which was approximately equivalent to the amount of glycolipid delivered when incorporated into the inoculum of 5 ϫ 10 6 CFU of modified BCG organisms) (Fig. 5D) . Similar results were obtained when up to 40-fold higher amounts (4 g) of the free glycolipids were injected without incorporation into the bacilli at the same or separate sites (data not shown). Enhancement of the CD8 T cell responses to the TB10.3/10.4 epitope (QIMYNPAM) was not observed in CD1D Ϫ/Ϫ mice (C57BL6 background) by ELISPOT assay for glycolipid-modified BCG, indicating that the adjuvant effect of the glycolipids was CD1d dependent (Fig. 5E) .
Enhanced vaccine efficacy of glycolipid-modified BCG
Immunization and challenge studies were performed to determine whether the enhanced CD8 ϩ T cell priming associated with ␣Gal-Cer/BCG or ␣-C-GalCer/BCG could improve protective immunity induced by BCG vaccination. C57BL/6 mice that were either naive or immunized 2 mo earlier by intradermal inoculation with live BCG, ␣GalCer/BCG, or ␣-C-GalCer/BCG were challenged by low-dose aerosol infection with virulent M. tuberculosis H37Rv, and CFU counts in tissues were determined at 3 and 6 wk after challenge. In naive mice, substantial growth in the lungs and dissemination to spleens were detected at 3 and 6 wk after challenge. However, vaccination with BCG, ␣GalCer/BCG, or ␣-C-GalCer/ BCG considerably reduced M. tuberculosis bacterial loads in both lungs and spleens of aerosol-challenged mice compared with naive controls (Fig. 6, A and B) . Interestingly ␣-C-GalCer/BCG vaccination protected significantly better than BCG, at the 3 wk time point, in both lungs and spleen. Immunization with ␣-C-GalCer/ BCG also showed a more prolonged effect on control of M. tuberculosis infection compared with BCG immunization, with reductions in CFU in both organs at 6 wk after challenge. Similar trends toward enhanced protection were observed with ␣GalCer/BCG immunization, although this was clearly less pronounced than with ␣-C-GalCer/BCG and achieved statistical significance only at the 6-wk time point in the lung. Histopathologic examination of the lungs from mice immunized with either BCG, ␣GalCer/BCG, or ␣-C-GalCer/BCG showed relatively mild inflammation with small and compact lymphocyte-rich granulomas compared with naive mice, which had extensive, poorly organized granulomatous lesions (Fig. 6C, top row) . A trend toward greater lymphocyte predominance of the lesions was apparent in areas of granulomatous inflammation of the lungs in ␣GalCer/BCG-or ␣-C-GalCer/BCGimmunized mice compared with naive or unmodified BCG-immunized mice (Fig. 6C, bottom row) .
To demonstrate that the adjuvant activity provided by the two glycolipids was due to and dependent on the specific activation of iNKT cells, we set up immunization and challenge experiments with CD1D Ϫ/Ϫ and J␣18 Ϫ/Ϫ knockout mice, both of which are completely deficient in iNKT cells but have normally functioning innate and adaptive immune systems in most other respects (25, 40) . There was no difference in protection between BCG-immunized and the glycolipid-modified BCG-immunized CD1D Ϫ/Ϫ or J␣18 Ϫ/Ϫ mice (Fig. 7) , demonstrating that iNKT cells were essential for enhanced protection induced in wild-type mice by immunization with ␣GalCer/BCG or ␣-C-GalCer/BCG compared with unmodified BCG.
Discussion
By developing a simple approach for incorporating synthetic ␣-galactosylceramides stably but reversibly into live mycobacteria, we describe a novel method that enables the activation of CD1d-restricted iNKT cells to be tightly coupled with the presentation of bacterial Ags during immunization with M. bovis BCG. This simple modification of BCG led to several marked changes in the immunologic effects of the vaccine. Although our studies have not resolved the exact site or sites in the bacteria in which the glycolipids become localized, we speculate that they are likely to be inserted into the lipid-rich outer membrane of the cell wall. Other possibilities include stable intercalation into the plasma membrane or possibly partitioning into cytosolic lipid storage bodies of the bacteria (41) . We observed that glycolipid-modified but not unmodified BCG induced a rapid and transient production of cytokines including IL-12p70 and IFN-␥, which was consistent with the known effects of in vivo activation of iNKT cells by ␣GalCer. DC maturation was enhanced by the incorporation of ␣GalCer into BCG and, most notably, CD8 ϩ T cell responses against mycobacterial protein Ags were significantly augmented. These immunologic effects were correlated with a significant improvement in the ability of glycolipid-modified BCG to stimulate protective immunity in a mouse model of vaccination followed by challenge with virulent M. tuberculosis.
Some microorganisms are known to contain glycolipids that are recognized as CD1d-presented Ags and have the capacity to directly activate iNKT cells during infection. This has been most clearly demonstrated for a group of Gram-negative bacteria known as sphingomonads (genus Sphingomonas or Novosphingobium), in which the major outer membrane glycolipids are ␣-glycosylceramides that strongly activate iNKT cells (42, 43) . Similarly, the spirochete Borrelia burgdorferi which causes Lyme disease has been shown to possess ␣-glycosylated glycerophospholipids which likewise function as CD1d-presented Ags for iNKT cells (44) . For organisms such as these which possess potent natural activators of iNKT cells, it is likely that the responses of this specialized T cell population are a prominent part of the initial immune response to infection and play a significant role in host defense. In contrast, in the case of mycobacteria such as BCG, it appears that strong endogenous iNKT cell-activating glycolipids are absent or not accessible, which prompted us to assess the possibility of increasing the immunogenicity of BCG by incorporation of synthetic ␣Gal-Cer. Previous work provides a strong rationale to the approach of using iNKT cell-activating glycolipids such as ␣GalCer as adjuvants for both cellular and humoral adaptive immune responses (45) . Initial proof of concept studies showed that i.v. administration of soluble protein Ag (OVA) together with ␣GalCer augmented both CD4 ϩ and CD8 ϩ Ag-specific T cell responses in mice (31) . Subsequent studies extended this approach to include the use of ␣GalCer to enhance adaptive immune responses against tumors or a variety of other antigenic challenges (46) . These have included the use of ␣GalCer in conjunction with a variety of types of vaccines against several pathogens, including malaria parasites (47), influenza virus (48), HIV (49), or Leishmania major (50) . Our findings reported in the current study are the first to our knowledge to evaluate the adjuvant role of ␣GalCer or its analog ␣-C-GalCer in the context of a vaccine against TB.
Although our studies indicated that unmodified BCG lacked the ability to rapidly and strongly stimulate iNKT cells, there is evidence that iNKT cells are able to sense and respond to mycobacterial infections. One previous study identified a glycolipid from BCG, phosphatidylinositol tetramannoside (PIM 4 ), that binds to CD1d, although in vitro assays suggest that it may be recognized by at most a small subset of iNKT cells (51) . In addition, mechanisms independent of specific bacterial Ag recognition could also lead to activation of iNKT cells during mycobacterial infections, as this is known to occur as a result of self-reactivity of iNKT cells coupled with the influence of inflammatory cytokines that may be prominently released during infection (52) . In fact, iNKT cells in mouse splenocytes become activated when cultured with M. tuberculosis-infected macrophages (53), and i.v. infection of mice with BCG has been shown to cause activation and expansion of iNKT cells in spleen and liver within 1 wk of infection (54) . However, our results indicated that iNKT cell activation by unmodified BCG is likely to be extremely weak or delayed, as we observed little or no cytokine production following a 16-h exposure of iNKT hybridoma cells to BCG-infected DCs or with naive splenocytes following 48 h of culture with BCG-infected DCs. This stands in marked contrast to the results obtained with ␣GalCer-modified BCG, which under the same experimental conditions gave rapid and robust cytokine production.
Although the direct effect of ␣GalCer incorporation was to endow BCG with the capacity to rapidly and powerfully activate iNKT cells, it was most likely the indirect secondary effects of iNKT cell activation that accounted for the improvement in vaccine efficacy against subsequent M. tuberculosis challenge. Multiple previous studies have generally led to the conclusion that iNKT cells exert relatively little if any effect on the course of TB in mice, since the outcome of M. tuberculosis infection is not significantly altered in CD1D Ϫ/Ϫ or J␣18 Ϫ/Ϫ mice that completely lack iNKT cells (55) (56) (57) (58) . On the other hand, strong activation of iNKT cells by administering ␣GalCer during established TB in mice (59) or augmentation of iNKT cells by adoptive transfer at the time of M. tuberculosis infection (53) are both associated with improved control of infection with reduced bacterial burden. Such effects are unlikely to account for the enhanced protective immunity we observed in our vaccination and challenge studies, since the M. tuberculosis challenge was not administered until 2 mo after the initial exposure to glycolipid-modified BCG. Long-term memory which could account for the vaccine-induced protection has generally not been observed with iNKT cells, which typically undergo depletion and induction of anergy following activation, with recovery to their baseline state over a period of several weeks (54, 60) . Thus, within the context of the vaccination protocol used in our studies, the beneficial effect of ␣GalCer incorporation into BCG most likely resulted from effects on priming and differentiation of memory T cells specific for mycobacterial peptide Ags, which represent the major known mediators of protective vaccineinduced adaptive immunity to M. tuberculosis (9) .
A striking result in our analysis was the impact of glycolipid incorporation on the initial priming of CD8 ϩ T cells and the subsequent augmentation of recall responses by this population. Our previous work has highlighted the ability of M. tuberculosis to actively inhibit and delay Ag presentation via MHC class I to CD8 ϩ T cells (5) , and additional experiments indicate that this immune evasion strategy is also retained in BCG (Fig. 5 and J. Hinchey and S. A. Porcelli, unpublished data). This striking effect on CD8
ϩ T cell responses stood in marked contrast to our findings on CD4 ϩ T cells, which appeared to be unaffected by the incorporation of iNKT cell-activating glycolipids into BCG. Although the mechanism responsible for the enhanced CD8 ϩ priming and memory T cell generation will require further analysis, one intriguing possibility is that the activation of iNKT cells could enhance MHC class I-restricted cross-presentation via the "detour pathway" which involves uptake of apoptotic mycobacteria-infected macrophages by activated DCs (61) . The glycolipid adjuvants used in our study are known to rapidly induce high levels of IFN-␥ in mice, which is associated with the development of strong CD8 ϩ T cell responses, regulates subsequent CD8 ϩ T cell contraction, and affects the formation of CD8 ϩ T cell memory (62).
The enhanced CD11c ϩ DC maturation observed with glycolipidmodified BCG, which most likely reflected at least in part the increased expression of CD40L on activated iNKT cells and its interaction with CD40 on DCs (31), could also promote CD8 ϩ T cell priming via the detour pathway or by other mechanisms of Ag cross-presentation. It is pertinent to note that the increased expression of maturation and costimulatory markers was delayed and reduced in magnitude in mice given unmodified BCG compared with those immunized with glycolipid-modified BCG. These differences would be expected to influence the strength and quality of T cell responses against mycobacterial Ags. Among the surface molecules that we observed to be increased by immunization with glycolipid-modified BCG was CD70, which has been identified as a key costimulatory factor expressed by a CD205 ϩ DC subset in mice that plays a predominant role in Ag cross-presentation to MHC class I-restricted CD8 ϩ T cells (63, 64) . Consistent with a possible role for CD70 in the enhanced priming of CD8 ϩ T cells that we observed, a recent study found that CD70 expression on DCs is essential for mediating the adjuvant effects of ␣GalCer on conventional CD8
ϩ T cells (65) . The direct comparison between ␣GalCer and its T H 1-biasing analog ␣-C-GalCer also proved interesting and revealing in our study. Although we observed a surprising lack of rapid cytokine secretion in response to ␣-C-GalCer-modified BCG both in vitro and in vivo (Fig. 2) , this formulation showed largely similar efficiency to conventional ␣GalCer-modified BCG for inducing DC maturation and in augmenting CD8 ϩ T cell priming in vivo (Figs.  3 and 5 ). Most notably, in vaccination and challenge studies, we found BCG modified with ␣-C-GalCer to be superior at inducing antimycobacterial protective immunity (Fig. 6) . The improvement in protective efficacy of BCG modified with ␣-C-GalCer both in the lungs and spleen is potentially attributable to the sustained IFN-␥ production and reduction of IL-4 levels associated with this analog of ␣GalCer (22) . Although the mechanism for the altered cytokine response to ␣-C-GalCer remains unresolved, we speculate based on recent studies of the mechanisms controlling the fine tuning of iNKT cell cytokine responses to ␣GalCer analogs that the increased hydrophobicity of this compound may be a key factor in producing its unique activities (66) . Conversely, the lack of enhanced protection in the spleens of mice immunized with ␣Gal-Cer/BCG may have reflected a relative T H 2 polarization resulting from the IL-4 production that is associated with administration of ␣GalCer. Our studies have not yet determined the reasons for the apparent disparity between the direct stimulation of iNKT cell cytokine production and the other more indirect effects of iNKT cell activation (DC maturation, CD8 ϩ T cell priming) with ␣-C-GalCer. However, these observations raise important considerations about which assays should be used to determine optimal formulations for vaccines containing iNKT cell-dependent adjuvants.
Most of the earlier studies on the adjuvant effect of ␣GalCer with vaccines against various infectious diseases have emphasized the importance of coadministration of this glycolipid with the respective vaccine to harness its adjuvant activity (47, 49, 50, 67) . We found this to be extremely important in the case of BCG, since our findings showed that simple coinjection of ␣GalCer or ␣-CGalCer did not enhance CD8 ϩ T cell responses, and this effect could only be achieved by the direct physical incorporation of the glycolipids into BCG (Fig. 5D ). This implies a requirement for tight linkage of the location or timing of iNKT cell activation with bacterial protein Ag processing and presentation to obtain the desired adjuvant effect. Our approach achieves this by guaranteeing the simultaneous delivery of the glycolipid and live BCG organisms into the same phagocytic cells. The direct incorporation approach also has important practical advantages including simplicity and ease of administration and the possibility of dose-sparing effects that could reduce production costs and minimize unwanted systemic side effects of a modified BCG vaccine. This dose-limiting effect may also mitigate the potential of ␣GalCer to cause depletion or anergy of iNKT cells, although this possibility has not yet been analyzed directly. Future studies to combine the current approach with additional modifications of BCG, including incorporation of compounds known to exert enhancing effects on CD4 ϩ T cell responses such as CpG oligodeoxynucleotides (23), could yield further improvements and lead to much needed advances in vaccines to combat the growing global epidemic of TB.
